Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

OBJECTIVES: To investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of 2-year methotrexate (MTX) therapy, compared with 2-year therapy with MTX alone. METHODS: MTX-naïve patients with early rheumatoid arthritis (RA) with poor prognostic factors were elig...

Descripción completa

Detalles Bibliográficos
Autores principales: Atsumi, Tatsuya, Tanaka, Yoshiya, Yamamoto, Kazuhiko, Takeuchi, Tsutomu, Yamanaka, Hisashi, Ishiguro, Naoki, Eguchi, Katsumi, Watanabe, Akira, Origasa, Hideki, Yasuda, Shinsuke, Yamanishi, Yuji, Kita, Yasuhiko, Matsubara, Tsukasa, Iwamoto, Masahiro, Shoji, Toshiharu, Togo, Osamu, Okada, Toshiyuki, van der Heijde, Désirée, Miyasaka, Nobuyuki, Koike, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738604/
https://www.ncbi.nlm.nih.gov/pubmed/28153828
http://dx.doi.org/10.1136/annrheumdis-2016-210246

Ejemplares similares

Ejemplares similares